Dihydroartemisinin-piperaquine

Eurartesim®
Alfasigma
3-day cure, artemisinin-based combination therapies (TPP-1)

Dihydroartemisinin-piperaquine

Access
-
Approved
Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5 kg
Dosing
  • Once daily for 3 days
Efficacy
  • 28-day PCR-corrected ACPR (adequate clinical and parasitological response) >97%
  • 42-day PCR-corrected ACPR 90%–95%
Key features
  • Comparatively long post-treatment protection
  • 2-year shelf life
Challenges
  • European Medicines Agency (EMA) cardiac monitoring guidance
  • Confirmed piperaquine resistance in Greater Mekong Sub-region
Status
  • First stringent regulatory approval by EMA in 2011
  • Approvals in 24 countries
  • Distributed 8.9 million doses to date  
Next milestone
  • Submit application for marketing authorisation for dispersible paediatric formulation to EMA
  • Publish results of cardiac safety and pharmacokinetics study in pregnancy in Tanzania
Project Director

Adam Aspinall